Discover BeiGene’s Broad Oncology Portfolio at the 2023 ASCO Annual Meeting: A Must-See Event!
BeiGene to Present Promising Early-Stage Data on BGB-A445 and BGB-11417 The Latest Breakthroughs in Oncology Treatment In a recent announcement, BeiGene, a leading biotechnology company, unveiled exciting data on two of its innovative products: anti-OX40 agnostic antibody BGB-A445 and BCL-2 inhibitor BGB-11417. These findings add to the extensive body of evidence supporting BeiGene’s core assets,…